Asenapine in the treatment of borderline personality disorder: An atypical antipsychotic alternative

International Clinical Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 120-123

  Martín Blanco, Ana ^a,b,c,d   Patrizi, Barbara ^e   Villalta, Laia ^a,b,d   Gasol, Xero ^e   Soler, Joaquim ^a,b,c,d   Gasol, Miquel ^e   Pascual, Juan C ^a,b,c,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e General de Catalunya Hospital   (Spain)

Author keywords

Antipsychotics; Asenapine; Borderline Personality Disorder; Treatment

Indexed keywords

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895075969     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000004     Document Type: Article

References (26)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. Barrachina J, Soler J, Campins MJ, Tejero A, Pascual JC, Alvarez E, et al. (2004). Validation of a Spanish version of the Diagnostic Interview for Borderlines- Revised (DIB-R) [i n Spanish]. Actas Esp Psiquiatr 32:293-298.
3. Gó mez-Beneyto M, Villar M, Renovell M, Pé rez F, Hernández M, Leal C, et al. (1994). The diagnosis of personality disorder with a modified version of the SCID-II in a Spanish clinical sample. J Pers Disord 8:104-110.
4. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
5. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J (2010). Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 30:106-115.
6. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J (2011). A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 72:349-355.
7. Klonsky ED (2008). What is emptiness Clarifying the 7th criterion for borderline personality disorder. J Pers Disord 22:418-426.
8. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F (2011). Borderline personality disorder. Lancet 377:74-84.
9. Lingiaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU Side Effect Rating Scale: A new comprehensive rating s cale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100.
10. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
11. Pascual JC, Mart́n-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, et al. (2010). A naturalistic study of changes in pharmacological prescription for borderline personality disorder in cl inical practice: From APA to NICE guidelines. Int Clin Psychopharmacol 25:349-355.
12. Pé rez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al. (2007). Modification of the Clinical Glo bal Impression (CGI) scale for use in borderline personality disorder patients (CGI-BPD). Actas Esp Psiquiatr 35:229-235.
13. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R (2010). Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 43:138-146.
14. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
15. Barr achina J, Soler J, Campins MJ, Tejero A, Pascual JC, Alvarez E, et al. (2004). Validation of a Spanish version of the Diagnostic Interview for Borderlines- Revised (DIB-R) [in Spanish]. Actas Esp Psiquiatr 32:293-298.
16. Gó mez-Beneyto M, Villar M, Renovell M, Pé rez F, Hernández M, Leal C, et al. (1994). The diagnosis of personality disorder with a modified version of the SCID-II in a Spanish clinical sample. J Pe rs Disord 8:104-110.
17. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
18. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J (2010). Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 30:106-115.
19. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J (2011). A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 72:349-355.
20. Klonsky ED (2008). What is emptiness Clarifying the 7th criterion for borderline personality disorder. J Pers Disord 22:418-426.
21. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F (2011). Borderline personality disorder. Lancet 377:74-84.
22. Lingiaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU Side Effect Rating Scale: A new comprehen sive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100.
23. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
24. Pascual JC, Mart́n-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, et al. (2010). A naturalistic study of changes in pharmacological prescription for borderline personality d isorder in clinical practice: From APA to NICE guidelines. Int Clin Psychopharmacol 25:349-355.
25. Pé rez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al. (2007). Modification of the Clinical Global Impression (CGI) scale for use in borderline personality disorder patients (CGI-BPD). Actas Esp Psiquiatr 35:229-235.
26. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R (2010). Long-te rm assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 43:138-146.